Agenus Inc (AGEN) 6.08 $AGEN Will Agenus (AGEN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Agenus Inc (AGEN) 6.08 $AGEN

Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:30PM CDT
Agenus (AGEN) is expected to report first-quarter 2015 results on Apr 23.
AGEN: 6.08 (+0.21), BIIB: 423.57 (+1.46), INCY: 107.98 (-1.20), IMGN: 9.96 (+0.01)

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)

Will Agenus (AGEN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 6:28AM CDT
Will Agenus (AGEN) Continue to Surge Higher?
AGEN: 6.08 (+0.21)

Antigenics Up 75.6% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Tue Apr 21, 9:47AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on December 8th, 2014 at $3.30. In approximately 4 months, Antigenics has returned 75.65% as of today's recent price of $5.80.
AGEN: 6.08 (+0.21)

Agenus to Report First Quarter 2015 Financial Results on April 23, 2015; Conference Call to Follow
Business Wire - Mon Apr 20, 6:50AM CDT
Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2015 financial results before the market opens on Thursday, April 23, 2015. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.
AGEN: 6.08 (+0.21)

3 Stocks That Could Double Your Money
George Budwell, The Motley Fool - Motley Fool - Sun Apr 19, 9:03AM CDT
If you're looking for a shot at doubling an investment, you'll want to take a look at the biotech industry. Biotech companies have been some of the best-performing stocks over the last couple of years thanks to the powerful confluence of numerous...
DVAX: 23.41 (-0.07), AGEN: 6.08 (+0.21), ACAD: 38.55 (-0.20)

Technical Coverage on Biotech Stocks -- Agenus, Raptor Pharma, KaloBios Pharma, Amicus Therapeutics, and Sarepta Therapeutics
PR Newswire - Fri Apr 17, 7:45AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AGEN: 6.08 (+0.21), KBIO: 0.57 (-0.02), RPTP: 10.56 (-0.17), SRPT: 13.52 (+0.04), FOLD: 11.97 (-0.35)

Antigenics Shares Up 68.5% Since SmarTrend's Buy Recommendation (AGEN)
Comtex SmarTrend(R) - Tue Apr 14, 9:15AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on December 8th, 2014 at $3.30. In approximately 4 months, Antigenics has returned 68.48% as of today's recent price of $5.56.
AGEN: 6.08 (+0.21)

Agenus buys Celexion's antibody assets
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 9:50AM CDT

AGEN: 6.08 (+0.21)

Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform
Business Wire - Wed Apr 08, 6:00AM CDT
--Combination with Agenus' mammalian Retrocyte Display(TM) technology to result in a uniquely powerful antibody platform
AGEN: 6.08 (+0.21)

Antigenics Up 59.7% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Mon Apr 06, 4:45PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on December 8th, 2014 at $3.30. In approximately 4 months, Antigenics has returned 59.70% as of today's recent price of $5.27.
AGEN: 6.08 (+0.21)

Don't Play With Propane - Cramer's Lightning Round (4/1/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 02, 6:02AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, April 1. Bullish Calls: Insys Therapeutics (NASDAQ: INSY ): "Good company. Makes money, but be careful because Johnson & Johnson (NYSE: JNJ )...
MNK: 122.95 (-2.22), KMI: 44.07 (+0.46), KSS: 75.91 (+0.96), MCK: 231.27 (-0.02), UNH: 117.81 (-1.47), ALK: 64.31 (-0.62), AGEN: 6.08 (+0.21), URBN: 42.17 (+0.03), DDS: 136.44 (-0.34), SBUX: 48.33 (-0.04), JNJ: 100.43 (+0.13), HCA: 77.53 (-0.15), INSY: 62.10 (+0.76), DNKN: 47.72 (+0.21), AMAT: 22.31 (+0.02), FGP: 23.82 (+0.22), BIG: 47.15 (+0.11), KPTI: 32.24 (-0.60)

'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
at The Street - Thu Apr 02, 5:00AM CDT
Cramer says to be careful on Insys Therapeutics, prefers Starbucks over Dunkin Brands and would buy Alaska Air.
KMI: 44.07 (+0.46), KSS: 75.91 (+0.96), MCK: 231.27 (-0.02), UNH: 117.81 (-1.47), ALK: 64.31 (-0.62), URBN: 42.17 (+0.03), SBUX: 48.33 (-0.04), AGEN: 6.08 (+0.21), DDS: 136.44 (-0.34), HCA: 77.53 (-0.15), DNKN: 47.72 (+0.21), INSY: 62.10 (+0.76), AMAT: 22.31 (+0.02), FGP: 23.82 (+0.22), BIG: 47.15 (+0.11), KPTI: 32.24 (-0.60)

Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
at The Street - Wed Apr 01, 7:22PM CDT
Supply is the true enemy of the bull and there's a lot of new supply hitting the markets, Cramer says.
CXO: 123.60 (+0.33), KMI: 44.07 (+0.46), TSLA: 219.44 (+10.03), KSS: 75.91 (+0.96), GE: 26.91 (+0.29), EMES: 51.50 (+0.20), FRPT: 22.79 (-0.60), UTX: 116.96 (+0.01), UNH: 117.81 (-1.47), FCX: 20.57 (+0.34), BPT: 67.68 (+1.51), SDRL: 11.33 (+0.28), SLB: 92.16 (+0.87), SBUX: 48.33 (-0.04), DNKN: 47.72 (+0.21), INSY: 62.10 (+0.76), LNCO: 12.34 (+0.46), AMAT: 22.31 (+0.02), CRZO: 52.72 (+0.32), FGP: 23.82 (+0.22), AAPL: 128.62 (+1.71), SIRI: 3.94 (unch), ABT: 48.35 (+1.23), MCK: 231.27 (-0.02), BMY: 66.60 (-0.21), ALK: 64.31 (-0.62), ARP: 9.04 (-0.02), URBN: 42.17 (+0.03), DDS: 136.44 (-0.34), AGEN: 6.08 (+0.21), PM: 83.69 (-0.36), HCA: 77.53 (-0.15), RDS.A: 62.36 (-0.06), TXMD: 7.17 (+0.01), BIG: 47.15 (+0.11), GDDY: 24.77 (-0.01), KPTI: 32.24 (-0.60)

Why It's Not Too Late to Buy Agenus, Inc. Stock
George Budwell, The Motley Fool - Motley Fool - Tue Mar 31, 8:01AM CDT
Shares of clinical-stage biopharma Agenus have been on fire since the company acquired 4-Antibody in February 2014, allowing it to greatly expand its activities in the burgeoning field of immuno-oncology. Despite some recent weakness because of a...
AGEN: 6.08 (+0.21), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), INCY: 107.98 (-1.20), GSK: 46.57 (-0.67)

53.6% Return Seen to Date on SmarTrend Antigenics Call (AGEN)
Comtex SmarTrend(R) - Mon Mar 30, 11:09AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on December 8th, 2014 at $3.30. In approximately 4 months, Antigenics has returned 53.64% as of today's recent price of $5.07.
AGEN: 6.08 (+0.21)

Antigenics Shares Up 59.1% Since SmarTrend's Buy Recommendation (AGEN)
Comtex SmarTrend(R) - Thu Mar 19, 9:20AM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on December 8th, 2014 at $3.30. In approximately 3 months, Antigenics has returned 59.09% as of today's recent price of $5.25.
AGEN: 6.08 (+0.21)

Scanning Biotech Equities -- Agenus, Amicus Therapeutics, Peregrine Pharma, Vanda Pharma, and Acorda Therapeutics
PR Newswire - Thu Mar 12, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AGEN: 6.08 (+0.21), VNDA: 9.99 (-0.25), PPHM: 1.42 (-0.01), ACOR: 33.34 (-1.33), FOLD: 11.97 (-0.35)

Agenus' (AGEN) CEO Garo Armen on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 27, 6:21PM CST

AGEN: 6.08 (+0.21)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI-Driven Software Growth Faces Profitability Hurdles

Updated Category News Views 153

AI and Growth: A Tale of Two Strategies Is AI the superhero we’ve been waiting for, or just another fad? The KeyBanc Capital Markets' 2026 AI x Software Benchmark throws more questions into the ring than it answers. This benchmark isn't just numbers on a page; it's a pulse check on how AI is reshaping the software landscape. Seeing AI-native firms grow at a dizzying 34%...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 155

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Dana Concludes Tender Offers for Senior Notes

Updated Category News Views 130

An Investor's Glance at Dana's Strategic Moves Dana Incorporated (NYSE: DAN) just pulled a bold move with their tender offers, snapping up a hefty $357,873,000 in outstanding principal on their senior notes. This isn’t just pocket change; folks holding out for securities can feel the tension of watching big numbers get shuffled around. You gotta wonder, what's the play...

Continue Reading
Noël Jolié's Cream Earns Spot on Oprah's List

Updated Category News Views 98

The Powerhouse of Oprah's Seal of Approval Ever notice what happens when Oprah drops a nod towards any brand? It's like Midas touching everything gold. That's exactly the scenario with Noël Jolié, a Chicago-based luxury body care operation, hitting the jackpot by landing its Velours Silken Body Cream on Oprah's Favorite Things 2026. You can't buy this kind of press,...

Continue Reading
Euroandinos Paita Closes Consent for 2037 Notes

Updated Category News Views 122

Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 227

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
PangeAI and Sky Blue Transform Data Center Decisions

Updated Category News Views 148

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 73

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 85

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 126

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming a Small Investment in Royal Caribbean Into Wealth

Updated Category News Views 156

The Power of Long-Term Investing in Royal Caribbean Investing in the stock market can often seem intimidating, especially for newcomers. However, a closer look at companies like Royal Caribbean Gr (NASDAQ: RCL) demonstrates the potential rewards of disciplined investing over time. Having shown remarkable performance, Royal Caribbean has an annualized return that exceeds...

Continue Reading
Immuron's Financial Growth and Clinical Progress Update

Updated Category News Views 149

Immuron's Consistent Growth and Exciting Projects Update Immuron Limited, a biopharmaceutical company based in Australia and publicly traded on the NASDAQ under the ticker IMRN and ASX ticker IMC.AX, is announcing some significant updates that reflect its ongoing commitment to healthcare innovation. The company's recent sales figures and progress in clinical trials...

Continue Reading
General Motors Growth Potential: Insights from Analysts

Updated Category News Views 281

General Motors Gets a Boost from Analysts In recent developments, General Motors Company (NYSE: GM) has garnered notable attention from financial analysts, particularly following Barclays' upgrade of the stock. The analysts play a vital role in assessing the market potential for stocks, and their insights can greatly influence investor confidence. Analyst Upgrades Impact...

Continue Reading
BioAge Labs Faces Class Action Lawsuit: Deadline Approaches Soon

Updated Category News Views 314

BioAge Labs Faces Class Action Lawsuit Investors of BioAge Labs, Inc. (NASDAQ: BIOA) are currently navigating a challenging landscape as a class action lawsuit is underway against the biopharmaceutical company. This underscores the importance for shareholders to stay informed about the developments following the company's recent stock performance and ensuing legal...

Continue Reading
Audit BEE Celebrates Dual Honors at Global Brand Awards

Updated Category News Views 177

Audit BEE Wins Prestigious Global Brand Awards Audit BEE has achieved remarkable recognition for its Excellence in Compliance and Advisory Leadership, recently celebrated at the prestigious Global Brand Awards. These awards, organized by Global Brands Magazine, acknowledge outstanding contributions from brands worldwide, showing the importance of excellence across various...

Continue Reading